ANTI-FGFR2 ANTIBODIES IN COMBINATION WITH CHEMOTHERAPY AGENTS IN CANCER TREATMENT
Application
US20260085123A1
Kind: A1
Mar 26, 2026
Assignee
FIVE PRIME THERAPEUTICS, INC.
Inventors
Helen L. COLLINS, James HNATYSZYN, Hong XIANG, Xiang ZHANG
Abstract
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
CPC Classifications
C07K 16/2863
A61K 9/0019
A61K 31/282
A61K 31/513
A61K 31/519
A61K 39/00
A61K 39/3955
A61P 35/00
A61P 35/04
A61K 2039/505
A61K 2039/545
C07K 2317/41
C07K 2317/732
C07K 2317/74
C07K 2317/76
C07K 2317/92
Filing Date
2025-05-05
Application No.
19199126